The clinical research industry has long been plagued by inefficiencies stemming from fragmented systems, poor user experiences and outdated technology stacks.

Wemedoo, a Swiss-based clinical data specialist, with its interoperable clinical research solution oomnia simplifies workflows, reduces administrative burdens and enables true interoperability in data management across all aspects of clinical research.

At the heart of Wemedoo’s success is the dynamic synergy of its founders, Nikola and Nina Cihoric – a duo with perfectly complementary expertise. Nikola, scientist and radio-oncologist, experienced the inefficiencies of clinical research firsthand. Nikola serves as the architect of Wemedoo’s groundbreaking interoperability approach, ensuring seamless data exchange and eliminating inefficiencies. Nina, meanwhile, unleashed the power of an interdisciplinary team, leveraging digital tools to create innovative, user-friendly solutions.

“Wemedoo is not just another tech provider in the eClinical space applying surface-level solutions. We are redefining how clinical trials should be managed globally addressing systemic issues that have frustrated users for years,” Nina explains.

Across the industry, frustration is growing. Researchers, clinicians and administrators are overwhelmed with endless admin work, repetitive tasks and error-prone processes. Instead of addressing the root of these issues, many solutions promise big results but fail to deliver real change. The Wemedoo success lies in the combination of deep clinical knowledge with technology that is used meaningfully.

“True progress comes from orchestrating these elements to create systems that actually work for the people using them,” Nikola says.

A defining strength behind Wemedoo mission is Alfred Scheidegger, the company’s Chairman and the Founder of Nextech Invest, a global venture capital.

“With decades of expertise in oncology biotech, Alfred, as one of the industry’s most visionary leaders, is an invaluable part of our team”, Nina reflects. “From their very first meeting, it was clear that Alfred’s vision aligned perfectly with our determination to address the inefficiencies of clinical trials.”

When systems fail researchers, patients pay the price

For Nikola Cihoric, the inefficiencies in clinical research were not hypothetical, they were part of his daily life. Working as a radio-oncologist, he experienced firsthand the frustration of fragmented systems and cumbersome workflows.

“When speaking with researchers, I hear the same complaints over and over,” he explains. “They do not want to adapt to the restrictions of a system. They want solutions that work on the fly, without endless clicks and integrations. Many feel like they are doing more administrative work than actual research.”

This disconnect between researchers and the systems they are forced to use has not only slowed the pace of discovery but also diverted resources away from what matters most: improving patient outcomes.

For Nikola, it was clear that the industry needed more than incremental fixes. A radical reimagining of how clinical data is collected, analyzed and shared is needed.

The solution: A unified, interoperable approach

The fundament of its approach is well-structured and standardized clinical data. “It’s not enough to rely on technology alone. It requires deep domain knowledge, intentionality, and adaptability to keep pace with the dynamic nature of medicine,” Nikola asserts.

Wemedoo’s flagship application, oomnia, integrates all core clinical trial functionalities – EDC, CTMS, RTSM, eTMF, eCOA, ePRO and eConsent into one cohesive system.

oomnia is designed to eliminate inefficiencies and empower researchers with a seamless, interoperable ecosystem. “User-centric design philosophy enables easy adaptation to the clinical workflows, without costly overhauls. It seamlessly integrates with any existing systems and applications,”  Nina says.

Nikola stressed the human impact of Wemedoo’s work. “Every delay in clinical trials represents a missed opportunity to save lives. We must implement practices that significantly increase productivity and efficiency to reduce industry costs because of the vital role we play in the production and supply of medicines to patients in need, worldwide,” he says.

The future: Interoperability as the foundation for AI-driven healthcare

“Interoperability is not just a buzzword,” Nikola says. “It is the precondition for realizing the full potential of AI in medicine. Without it, we cannot achieve the efficiency, precision, and scalability that modern healthcare demands.

“Our mission is not just to solve today’s problems. It is to build a future where clinical trials are faster, smarter, and more patient-centric. Because when we simplify clinical trials, we do not just save time – we save lives.”